MedTrace Logo

Biomime Stent in All-comers PCI Patients Registry

NCT02398955 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2015-03-26

No results posted yet for this study

Summary

Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 μm) and a biodegradable polymer licensed for the treatment of de novo coronary lesions. However no data regarding the efficacy and safety of this stent in an "all-comers" patient population treated with percutaneus coronary interventions (PCI) have been published so far. In this registry the investigators aimed to collect clinical and angiographic information about an extensive "all-comers" employ of this novel stent.

Conditions

Interventions

DEVICE

percutaneous coronary intervention

percutaneous coronary angioplasty with implantation of at least one Biomime stent

Sponsors & Collaborators

  • Azienda Ospedaliero Universitaria Maggiore della Carita

    lead OTHER

Principal Investigators

  • Alessandro Lupi, MD · Azienda Ospedaliero Universitaria Maggiore della Carita

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398955 on ClinicalTrials.gov